Sage Therapeutics (SAGE)
(Real Time Quote from BATS)
$12.59 USD
+0.30 (2.44%)
Updated Jul 22, 2024 03:05 PM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SAGE 12.59 +0.30(2.44%)
Will SAGE be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SAGE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SAGE
SAGE Rides on Zurzuvae Sales, Pipeline Setbacks a Concern
SAGE's Huntington's Disease Study Meets Primary Endpoint
SAGE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Tops Revenue Estimates
Biogen (BIIB) Q1 Earnings Beat, Stock Up on Alzheimer Drug Uptake
Other News for SAGE
Netflix To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Friday
Mizuho Securities Sticks to Their Hold Rating for SAGE Therapeutics (SAGE)
Sage Therapeutics price target lowered by $2 at Mizuho, here's why
Sage Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024
Noteworthy Tuesday Option Activity: SAGE, OPEN, CORZ